Phase I clinical trial - Phases précoces tumeurs solides

MK4621-002-02
Phases précoces tumeurs solides
Ouvert depuis le: 06.16.2019
Site: Paris
Public cible
Adulte
A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors
Description de l'essai

The purpose of this study is to evaluate safety and tolerability, pharmacokinetics (PK), and preliminary antitumor activity of intratumoral (IT) / intralesional injections of MK-4621 delivered via the JetPEI·in vivo linear polyethylenimine nucleic acid delivery system (MK-4621/JetPEI·) as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.